The winter baby killer has a nemesis! The first drug available for respiratory syncytial virus infection in infants on the domestic market
穿越夜时空簿
发表于 2024-1-3 17:23:38
1297
0
0
On January 2nd, AstraZeneca and Sanofi jointly developed a long-acting monoclonal antibody called Nirsevimab, which was officially approved for marketing by the National Medical Products Administration of China. It is used to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants. The drug is expected to be launched in China during the 2024-2025 RSV infection season.
Respiratory syncytial virus (RSV) is a common respiratory virus. Due to the fact that cells infected with the virus fuse together, forming a large cell structure similar to a "syncytial body", they are vividly referred to as respiratory "syncytial" viruses. RSV is more prevalent in winter and early spring, and the epidemic season in the Northern Hemisphere usually starts in October or November, and can last until April or May of the following year. The peak period usually occurs in January or February.
China is one of the countries with a high incidence of RSV worldwide. Research shows that from 2009 to 2019, influenza virus and RSV ranked among the top two pathogens detected in the total population of acute respiratory infections in China, with proportions of 28.5% and 16.8%, respectively.
Research has shown that over 60% of acute lower respiratory tract infections in young children and 80% of infections in infants under 1 year old are caused by RSV. According to data from the World Health Organization, syncytial virus infection is the leading cause of hospitalization or even death in children under the age of five due to virus infection, hence the nickname "winter baby killer".
The newly approved Nissevir monoclonal antibody is the first and only approved preventive measure in China to protect the general infant population against RSV infection, covering healthy full-term infants, premature infants, and infants who are susceptible to severe RSV infection due to special health conditions. The approval of niseverumab in China is mainly based on the results of three key clinical trials and clinical research and development projects in China. For all clinical trial endpoints, a single injection of niseverumab has shown consistent efficacy in treating lower respiratory tract diseases caused by respiratory syncytial virus, with a sustainable protection period of five months, which is a typical RSV infection season.
In response, Professor Liu Hanmin, Dean of West China Second Hospital of Sichuan University and Principal Investigator (PI) of Phase III Clinical Trials of Nisevirumab in China, said, "This approval for marketing in China not only reduces the disease burden caused by syncytial virus infection in children and families, but also hopes to reduce the burden on the medical system caused by respiratory diseases in pediatrics. This will contribute an important force to the prevention and control of syncytial virus in China."
It is worth noting that as early as March 2017, AstraZeneca and Sanofi announced a cooperation agreement for the development and commercialization of nisetizumab. According to the terms of the agreement, AstraZeneca is responsible for product development and production, while Sanofi is responsible for product commercialization and revenue measurement. The two companies share costs and profits in all regions except the United States. The revenue generated by AstraZeneca based on this agreement is classified as alliance revenue and partnership revenue in the company's financial statements.
AstraZeneca's General Manager in China, Lai Minglong, pointed out that Nisetumab has filled the gap in the prevention of respiratory syncytial virus in newborns and infants in China, and is of great significance for protecting the health of Chinese infants. We hope that this drug can provide an "immune umbrella" for newborns and infants during their first RSV infection season. In the future, AstraZeneca will also accelerate research and development innovation, further enriching its product pipeline.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- On the first trading day after NVIDIA's stock split, its market value continued to rise slightly, surpassing Apple's market value
- Xiaopeng Motors: The first product in the MONA series is named "Xiaopeng M03"
- Xiaopeng Motors: The first product in the MONA series named Xiaopeng M03
- Before the United States! What is the safety and efficacy of the world's first weekly insulin injection approved in China
- The world's first! French regulatory authorities sue NVIDIA
- Alibaba launches the first AI picture book tool in China to care for children with autism
- JD Group and Hailan Group have reached a strategic cooperation and will open the first JD Aolai offline store
- Modner claims that the company has reached a joint agreement with Mitsubishi Tanabe Pharmaceuticals to promote the company's mRNA respiratory vaccine portfolio in Japan
- NIO's first fourth substitution power station in Beijing officially goes online
- New breakthrough in AI chips! SK Hynix, the world's first to achieve mass production of 12 layer HBM3E products, saw its stock price surge by nearly 9%
-
AIエクスプレスによると、10月3日、米株の人気の中概株盤の前が低くなり、ピッピッピッと5%近く下落し、相多、名創優品、小鵬自動車は3%超下落し、百度、蔚来自動車、京東は2%超下落した。 ...
- SOGO
- 前天 17:06
- 支持
- 反对
- 回复
- 收藏
-
ナスダック中国の金龍指数は5%超上昇し、楽しい自動車は120%超上昇し、金山雲は18%超上昇し、ピシャリと12%超上昇し、子牛の電動、怪獣の充電は10%超上昇し、愛奇芸は8%超上昇し、テンセント音楽、新東方は7%超上昇 ...
- hecgdge4
- 前天 10:28
- 支持
- 反对
- 回复
- 收藏
-
10月1日、理想自動車が9月に納入したデータによると、9月に理想自動車が新車53709台を納入し、前年同月比48.9%増となった。 今年第3四半期、理想自動車は前年同期比45.4%増の152831台を納入した。今年9月30日現在、 ...
- 就放荡不羁就h
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
EUが中国の電気自動車に関税を課す方針、独首相と財務相が反発 ドイツ連邦のショルツ首相は現地時間の10月2日、EUが中国の電気自動車に一時的な補助金税を課す紛争を解決するために中国と交渉することを表明した。 ...
- 寒郁轩良
- 昨天 10:13
- 支持
- 反对
- 回复
- 收藏